Member Info for Kaeren

If keys and bowl is reference to Tootramp signing off as me then I think not .

I preferred your contributions yesterday Toptramp x

It may be my ignorance but if you asked me what Roche were famous for I could not answer , same with multiple well known huge diagnostic companies. I don't want the company known for one product , steady sales in multiple products would be my preference.

Hope so.

Larry , the Amf twitter post re Bio , what role did Oddo play ?

Anyone know if we've binned them off ?

Hi Ak , no idea .

Yeah that was announced this a.m so why suspend ( if it is tonight )

https://www.boursedirect.fr/fr/actualites/categorie/divers/biosynex-cotation-suspendue-boursier-bb59ccb976e82475c5bbe7af646679e2e054dbca

I can't read French , might be wrong.

Biosynex acquiert l'italien Bigix Pharma
information fournie parAOF•22/09/2022 à 08:57

(AOF) - Biosynex a signé un accord portant sur l'acquisition de 100% du capital de la société italienne Bigix Pharma auprès de ses associés fondateurs. La finalisation de cette acquisition interviendra dans les prochains jours, après la réalisation des formalités requises en Italie. Bigix Pharma possède déjà un portefeuille clients de plus de 5.000 pharmacies, démarchées par sa force de vente, composée de plus de 40 agents commerciaux indépendants.

Bigix Pharma distribue différentes gammes de produits dans le segment du matériel médical et a réalisé en 2021 un chiffre d'affaires d'environ 2,9 millions d'euros.

Avec cette acquisition, Biosynex va pouvoir pénétrer le marché italien de la Pharmacie qui représente plus de 20 000 points de ventes et lancer ses propres gammes d'autotests, de thermomètres, de produits anti-moustiques, de bouillottes sous licence Disney et des autres produits phares du catalogue.

Après l'ouverture de deux filiales en Suisse en 2020 et au Benelux en juin 2022, Bigix Pharma devient en Italie la 3ème filiale européenne de Biosynex , renforçant ainsi le réseau européen des pharmacies et parapharmacies avec plus de 50.000 points de ventes visités en direct par les forces de ventes du groupe.

AOF - EN SAVOIR PLUS

Une course inéluctable aux nouveaux blockbusters

Le brevet du produit vedette de Merck, l'anticancéreux Keytruda, qui représente plus de 35% de ses ventes, arrive à échéance en 2028. En dépit de la perte, depuis 2019, des brevets de ses trois produits vedette (Avastin, Herceptine, Rituxan) Roche a su, lui, renouveler son portefeuille en mettant sur le marché de nouvelles molécules. Toutefois la découverte et le lancement de nouveaux médicaments sont de plus en plus coûteux. AstraZeneca dépense environ 6 milliards de dollars par an en R&D dans une industrie pharmaceutique où la durée de vie d'un brevet ne dure que dix à quinze ans. Cela amène les laboratoires à se désengager de certaines activités. Ainsi J&J, Pfizer, GSK et, sans doute, Novartis prochainement préfèrent se recentrer sur les médicaments de spécialité et abandonnent toute activité annexe.

Bio suspended .

Look it up , I'm not spoon feeding you , too many Dribblers already xx

Professor Jo Martin, President of the Royal College of Pathologists and Professor of Pathology at Queen Mary University of London was thrilled with the outcome of the Cicerio trial . Don't be a silly Billy, you are well aware as you held at the time. Great endorsement from the president of the Royal collage of pathologists and proff at an NHS hospital. That lady and all who worked with her mastered the " oh so complex procedure" The trial was the precursor to the contract. It worked so well , we were awarded the contract :)

No idea 1iats but I'd have her on speed dial.

Would certainly be callig this lady as an expert witness. She definitely had no issues with the q16's or q32's. Back to sleep mode.

https://www.rcpath.org/profession/publications/annual-reports/annual-report-2019-2020/bringing-testing-to-those-who-are-most-vulnerable.html

Holding a chunk of Ang , don't comment , never held a share in this arena before , so on a steep learning curve.

Well used to DRB from NCYT , he is exceptionally well researched from my exposure to him and freely admits he Trades a chunk of his position. I take it as a positive if he makes me consider something I hadn't previously entertained.
Can get vocal in quite periods if gearing up for a trade but not a deramper imo only.

Byp where have your twitter posts gone ?

Old RNS from OCT 19 , obviously don't know what this generated in 2020 as covid took over and very few respiratory illnesses due to mask wearing and lock downs , same in winter flu season 2021.
2022 expected to follow Oz , high level of respiratory viruses ( non covid )
As this was a five year manufacturing agreement, I want to see if we can spot any of our new products sitting in the same sales arena. I can't remember if we ever established who this was. Any clues ?

Molecular respiratory panel ready for US market
Mon, 7th Oct 2019 07:00

RNS Number : 9023O
Novacyt S.A.
07 October 2019

Novacyt S.A.



("Novacyt", the "Company" or the "Group")
New molecular respiratory panel ready for the US market
Multiplex test identifies up to 37 respiratory pathogens



Paris, France and Camberley, UK - 7 October 2019 - Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces the succesful development of a new molecular diagnostic multiplex test for respiratory infections, which is ready for launch in North America in time for the US cold and flu season.
Novacyt's molecular business unit Primerdesign, has completed the design and development of the molecular respiratory panel based on a 384 well plate format for use by its North American business partner in their CLIA approved diagnostic testing laboratory network. Primerdesign has designed the multiplex test to identify 37 respiratory pathogens, which makes it one of the most comprehensive respiratory panels available in the market today. In addition to identifying a large number of respiratory disease pathogens, the new diagnostic product has been designed with proprietary freeze-drying technology to stabilise the product to optimise its ease of use and performance.
Primerdesign will supply this product under a five year manufacturing agreement as its partner launches the new respiratory panel in the US market through its own clinical testing laboratories to provide a Laboratory Developed Diagnostic test result for its customers. The initial order for $105,000 has been received by Primerdesign

Tenuous - Midatech , needs funding / partnership , one of Gayle Sextons interests , but not our normal field. That's it for looking duty calls.

Oliver sexton , Linear diagnostics , seed funded ? Target ?